EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. More Details
Reasonable growth potential with mediocre balance sheet.
Share Price & News
How has EDAP TMS's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EDAP's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: EDAP underperformed the US Medical Equipment industry which returned 24.8% over the past year.
Return vs Market: EDAP underperformed the US Market which returned 18.5% over the past year.
Price Volatility Vs. Market
How volatile is EDAP TMS's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWill The ROCE Trend At EDAP TMS (NASDAQ:EDAP) Continue?
4 months ago | Simply Wall StHow Does EDAP TMS S.A. (NASDAQ:EDAP) Affect Your Portfolio Volatility?
5 months ago | Simply Wall StThe EDAP TMS (NASDAQ:EDAP) Share Price Is Down 50% So Some Shareholders Are Wishing They Sold
Is EDAP TMS undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: EDAP ($4.92) is trading above our estimate of fair value ($1.34)
Significantly Below Fair Value: EDAP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: EDAP is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: EDAP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EDAP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EDAP is overvalued based on its PB Ratio (4.4x) compared to the US Medical Equipment industry average (4.1x).
How is EDAP TMS forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EDAP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: EDAP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EDAP's is expected to become profitable in the next 3 years.
Revenue vs Market: EDAP's revenue (19.6% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: EDAP's revenue (19.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EDAP's Return on Equity is forecast to be high in 3 years time
How has EDAP TMS performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EDAP is currently unprofitable.
Growing Profit Margin: EDAP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EDAP is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare EDAP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EDAP is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.5%).
Return on Equity
High ROE: EDAP has a negative Return on Equity (-6.13%), as it is currently unprofitable.
How is EDAP TMS's financial position?
Financial Position Analysis
Short Term Liabilities: EDAP's short term assets (€42.1M) exceed its short term liabilities (€17.5M).
Long Term Liabilities: EDAP's short term assets (€42.1M) exceed its long term liabilities (€8.2M).
Debt to Equity History and Analysis
Debt Level: EDAP's debt to equity ratio (18%) is considered satisfactory.
Reducing Debt: EDAP's debt to equity ratio has increased from 17.2% to 18% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if EDAP has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EDAP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is EDAP TMS current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EDAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EDAP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EDAP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EDAP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EDAP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Marc Oczachowski (50 yo)
Mr. Marc Oczachowski has been Chief Executive Officer of EDAP TMS SA since March 31, 2007 and its Executive Director since July 1, 2017. Mr. Oczachowski serves as Executive Chairman of the Board at EDAP TM ...
|Executive Chairman & CEO||13.58yrs||no data||no data|
|Chief Financial Officer||5.25yrs||no data||no data|
|Investor Relations Officer and Secretary||no data||no data||no data|
|Vice President of Global Sales & Marketing||0.42yr||no data||no data|
Experienced Management: EDAP's management team is seasoned and experienced (5.3 years average tenure).
|Executive Chairman & CEO||13.58yrs||no data||no data|
|Independent Director||11.33yrs||no data||no data|
|Independent Director||23.5yrs||no data||no data|
|Independent Director||18.08yrs||no data||no data|
|Director||0.33yr||no data||no data|
|Independent Director||11.25yrs||no data||no data|
Experienced Board: EDAP's board of directors are seasoned and experienced ( 11.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
EDAP TMS S.A.'s company bio, employee growth, exchange listings and data sources
- Name: EDAP TMS S.A.
- Ticker: EDAP
- Exchange: NasdaqGM
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$143.377m
- Shares outstanding: 29.14m
- Website: https://www.edap-tms.com
Number of Employees
- EDAP TMS S.A.
- Parc dActivites la Poudrette-Lamartine
- 4/6, rue du DauphinE
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EDAP||NasdaqGM (Nasdaq Global Market)||Yes||SPONSORED ADR||US||USD||Aug 1997|
|EDA||DB (Deutsche Boerse AG)||Yes||SPONSORED ADR||DE||EUR||Aug 1997|
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/20 23:32|
|End of Day Share Price||2020/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.